• Explore /
  • Poster
  • / Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).

Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).

Abstract Poster

Authors

null

Michael J. Overman

The University of Texas MD Anderson Cancer Center, Houston, TX

Michael J. Overman , Patricia LoRusso , John H. Strickler , Sandip Pravin Patel , Stephen John Clarke , Anne M. Noonan , Thiru Prasanna , Manik A. Amin , John J. Nemunaitis , Jayesh Desai , Kenneth John O'Byrne , Thomas J. George Jr., Judson Englert , Dewei She , Zachary A. Cooper , Yuling Wu , Anis Khan , Rakesh Kumar , Johanna C. Bendell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

02503774

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4123)

DOI

10.1200/JCO.2018.36.15_suppl.4123

Abstract #

4123

Poster Bd #

312

Abstract Disclosures

Similar Posters

First Author: Johanna C. Bendell

First Author: John Ebben

First Author: Francisco Robert

First Author: Sant P. Chawla